Share on StockTwits

Gilead Sciences (NASDAQ:GILD) Director John Francis Cogan sold 5,000 shares of the stock on the open market in a transaction dated Thursday, August 21st. The stock was sold at an average price of $101.09, for a total value of $505,450.00. Following the completion of the transaction, the director now directly owns 42,405 shares of the company’s stock, valued at approximately $4,286,721. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 2.67% during mid-day trading on Monday, hitting $106.74. 10,085,542 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $58.50 and a 1-year high of $105.16. The stock has a 50-day moving average of $92. and a 200-day moving average of $82.00. The company has a market cap of $161.4 billion and a price-to-earnings ratio of 23.55.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.

GILD has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $102.00 to $115.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $105.55.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.